THC Drug Significantly Reduces Nightmares in PTSD Sufferers
Translated & summarized from Bizportal by baba
A new study in Nature Medicine shows that dronabinol, a synthetic THC drug, significantly reduced nightmares in PTSD patients. Over a third of participants stopped experiencing nightmares entirely after ten weeks of treatment.
The story in 5 lines · by baba
- THC drug dronabinol significantly reduced nightmares in PTSD patients.
- Over a third of participants stopped having nightmares completely.
- The study was a ten-week, double-blind trial with 171 participants.
- Side effects were mild, and no serious adverse events were reported.
- The drug specifically targets nightmares, not overall PTSD severity.
A new study published in Nature Medicine in August 2026 found that a synthetic THC-based drug, dronabinol, significantly reduced nightmares in individuals suffering from post-traumatic stress disorder (PTSD). The ten-week, randomized, double-blind trial involved 171 participants with PTSD and frequent, severe nightmares. 87 participants received dronabinol drops nightly before sleep, while 84 received a placebo that mimicked the taste and appearance of cannabis.
The primary outcome measured was the severity of nightmares on a scale of zero to eight. Participants taking dronabinol experienced an average reduction of 3.7 points in nightmare severity, compared to a 2.2-point reduction in the placebo group. This difference was statistically significant, indicating a medium to large effect size.
Crucially, over a third of participants receiving dronabinol reported no nightmares at all by the end of the ten-week study. An additional 21% reported their nightmare burden was cut in half, and about five out of six participants noted a marked improvement in their general condition. Side effects were mild to moderate, including dizziness, headaches, and increased appetite, with no serious adverse events or withdrawal symptoms observed.
Professor Stefan Röpke of Charité University Hospital Berlin, who led the study, suggested that THC may reduce REM sleep dreaming activity, thereby alleviating nocturnal stress responses. He emphasized that more than a third of patients treated with dronabinol reported no longer experiencing nightmares after ten weeks.
This research is particularly relevant to Israel, where medical cannabis is used for PTSD, and where the foundational research on THC originated at the Weizmann Institute. However, the study did not show a reduction in overall PTSD severity or associated depression, suggesting the drug specifically targets nightmares and sleep rather than all aspects of the disorder. Long-term safety, efficacy, and potential tolerance issues remain unknown, and the study received pharmaceutical company funding.